Skip to main content
. Author manuscript; available in PMC: 2010 Sep 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):106–113. doi: 10.1097/QAI.0b013e3181a4f9c4

Figure 2. Effect of Failure Rates and Viral Load Cost on Cost-Effectiveness of a Third HAART Regimen.

Figure 2

The incremental cost-effectiveness ratio of strategy C compared with the WHO strategy with viral load monitoring as a function of rates of failure and price of viral load monitoring. With lower rates of failure, fewer people require advanced HAART regimens, and the incremental benefits of those regimens diminishes, making the incremental cost-effectiveness ratio higher. The incremental cost-effectiveness ratio depends on the per-test cost of viral load monitoring.